These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22496391)

  • 1. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
    Su H; Boulton DW; Barros A; Wang L; Cao K; Bonacorsi SJ; Iyer RA; Humphreys WG; Christopher LJ
    Drug Metab Dispos; 2012 Jul; 40(7):1345-56. PubMed ID: 22496391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
    Boulton DW
    Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
    Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
    Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic study of saxagliptin in healthy Chinese subjects.
    Li H; Yang L; Tou CK; Patel CG; Zhao J
    Clin Drug Investig; 2012 Jul; 32(7):465-73. PubMed ID: 22668067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
    Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
    Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excretion, metabolism, and pharmacokinetics of 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide, a selective cannabinoid receptor antagonist, in healthy male volunteers.
    Miao Z; Sun H; Liras J; Prakash C
    Drug Metab Dispos; 2012 Mar; 40(3):568-78. PubMed ID: 22187487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
    Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
    Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.
    Upreti VV; Boulton DW; Li L; Ching A; Su H; Lacreta FP; Patel CG
    Br J Clin Pharmacol; 2011 Jul; 72(1):92-102. PubMed ID: 21651615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
    Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.
    Vourvahis M; Gleave M; Nedderman AN; Hyland R; Gardner I; Howard M; Kempshall S; Collins C; LaBadie R
    Drug Metab Dispos; 2010 May; 38(5):789-800. PubMed ID: 20124396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential inhibition of sildenafil and macitentan on saxagliptin metabolism.
    Dai GX; Tan W; Shen Y; Lin D; Xu RA; Lin Q; Wei Z
    Toxicol Appl Pharmacol; 2024 May; 486():116934. PubMed ID: 38663673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
    Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
    Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
    Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
    Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
    He H; Tran P; Yin H; Smith H; Batard Y; Wang L; Einolf H; Gu H; Mangold JB; Fischer V; Howard D
    Drug Metab Dispos; 2009 Mar; 37(3):536-44. PubMed ID: 19074975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.
    Kumar S; Tan EY; Hartmann G; Biddle Z; Bergman AJ; Dru J; Ho JZ; Jones AN; Staskiewicz SJ; Braun MP; Karanam B; Dean DC; Gendrano IN; Graves MW; Wagner JA; Krishna R
    Drug Metab Dispos; 2010 Mar; 38(3):474-83. PubMed ID: 20016053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Open-Label Randomized Crossover Study.
    Ren S; Boulton DW
    Clin Pharmacol Drug Dev; 2019 May; 8(4):549-558. PubMed ID: 30500110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms.
    Lee HK; Moon JK; Chang CH; Choi H; Park HW; Park BS; Lee HS; Hwang EC; Lee YD; Liu KH; Kim JH
    Drug Metab Dispos; 2006 Jul; 34(7):1090-5. PubMed ID: 16581944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.
    Sigafoos JF; Bowers GD; Castellino S; Culp AG; Wagner DS; Reese MJ; Humphreys JE; Hussey EK; O'Connor Semmes RL; Kapur A; Tao W; Dobbins RL; Polli JW
    Drug Metab Dispos; 2012 Nov; 40(11):2090-101. PubMed ID: 22851617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotransformation Pathways and Metabolite Profiles of Oral [
    Pusalkar S; Zhou X; Li Y; Cohen L; Yang JJ; Balani SK; Xia C; Shyu WC; Lu C; Venkatakrishnan K; Chowdhury SK
    Drug Metab Dispos; 2020 Mar; 48(3):217-229. PubMed ID: 31911485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.